Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? by Nadiya Hussain, Muntaha Naeem, David J. Pinato

Get full text

Recent advances in HIV-associated Kaposi sarcoma [version 1; peer review: 2 approved] by Alessia Dalla Pria, David J. Pinato, Margherita Bracchi, Mark Bower

Get full text

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinomaKey points by Coskun O. Demirtas, Antonio D’Alessio, Lorenza Rimassa, Rohini Sharma, David J. Pinato

Get full text

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival by Lisa Yang, Sruthi Murthy, Alessio Cortellini, Alessio Cortellini, Emma A. Lim, Michael Gonzalez, David J. Pinato, David J. Pinato, Mariana Abdel-Malek, Sarah Mahmoud, Niamh M. Martin, Niamh M. Martin

Get full text

Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review by David J Pinato, Kerigo Ndirangu, Richard S Finn, Zahra Ramji, Peter Galle, Catherine Ruth Mitchell, Gabrielle Sophie Redhead

Get full text

558 A systematic review of anti-drug antibodies related to CTLA-4, PD-1 or PD-L1 inhibitors across tumour types by David J Pinato, Peter R Galle, Kerigo Ndirangu, Catherine R Mitchell, Zahra Ramji, Gabrielle Redhead, Richard Finn

Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior by David J. Pinato, James R. Black, Sebastian Trousil, Roberto E. Dina, Pritesh Trivedi, Francesco A. Mauri, Rohini Sharma

Get full text

Antibiotic therapy and outcome from immune-checkpoint inhibitors by David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi, Mark Bower

Get full text

Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram by Agnese Losurdo, Agnese Losurdo, Angelo Dipasquale, Laura Giordano, Pasquale Persico, Pasquale Persico, Elena Lorenzi, Antonio Di Muzio, Antonio Di Muzio, Chiara Barigazzi, Chiara Barigazzi, James Korolewicz, Aman Mehan, Oreoluwa Mohammed, Benhard Scheiner, David J. Pinato, David J. Pinato, Armando Santoro, Armando Santoro, Matteo Simonelli, Matteo Simonelli

Get full text

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis by Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, David J. Pinato, David J. Pinato, Christian Ottensmeier, Sara Campos, Sethupathi Muthuramalingam, Samuel Chan, Fabio Gomes, Giuseppe L. Banna

Get full text

Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity by Zhen Zhang, David Rafei-Shamsabadi, Saskia Lehr, Nico Buettner, Rebecca Diehl, Daniela Huzly, David J Pinato, Robert Thimme, Frank Meiss, Bertram Bengsch

Get full text

712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell... by David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo

An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. by David J Pinato, Chara Stavraka, Michael J Flynn, Martin D Forster, Séan M O'Cathail, Michael J Seckl, Rebecca S Kristeleit, David Olmos, Samantha J Turnbull, Sarah P Blagden

Get full text

A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. by Vincenzo Libri, Andrew P Brown, Giulio Gambarota, Jonathan Haddad, Gregory S Shields, Helen Dawes, David J Pinato, Ethan Hoffman, Peter J Elliot, George P Vlasuk, Eric Jacobson, Martin R Wilkins, Paul M Matthews

Get full text

Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials by Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Charalampos-Vlasios Stikas, Alessandra Gennari, Bruno Vincenzi, Mark R. Openshaw, Marianna Silletta, Matthias Pinter, Alessio Cortellini, Lorenza Scotti, Antonio D’Alessio, David J. Pinato

Get full text

Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression by Robert Brown, Sadaf Ghaem-Maghami, Marina Natoli, David J Pinato, John Gallon, Haonan Lu, Ala Amgheib, Francesco A Mauri, Teresa Marafioti, Ayse U Akarca, Ines Ullmo, Jacey Ip, Eric O Aboagye, Anastasios Karadimitris

Get full text

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis by Arndt Vogel, Lorenza Rimassa, Hui-Chan Sun, Ghassan K. Abou-Alfa, Anthony El-Khoueiry, David J. Pinato, Javier Sanchez Alvarez, Monica Daigl, Panos Orfanos, Michael Leibfried, Marie-Hélène Blanchet Zumofen, Vincent E. Gaillard, Philippe Merle

Get full text

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma by David J. Pinato, Alessio Cortellini, Ajithkumar Sukumaran, Tom Cole, Madhava Pai, Nagy Habib, Duncan Spalding, Mikael H. Sodergren, Maria Martinez, Tony Dhillon, Paul Tait, Robert Thomas, Caroline Ward, Hemant Kocher, Vincent Yip, Sarah Slater, Rohini Sharma

Get full text

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors by Yan Zhang, Andrés Cervantes, Stephane Champiat, Aurélien Marabelle, Patricia LoRusso, Jason J Luke, Robert Haddad, David J Pinato, Dejan Juric, María de Miguel, Won Seog Kim, Xiaobin Yuan, Peter J Hosein, Anupam M Desai, Yuanxin Rong

Get full text

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma by David J. Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, Antonio D’Alessio, Claudia A.M. Fulgenzi, Bernhard Scheiner, Matthias Pinter, Guo Wei, Julie Schneider, Donna R. Rivera, Richard Pazdur, Marc R. Theoret, Sandra Casak, Steven Lemery, Lola Fashoyin-Aje, Alessio Cortellini, Lorraine Pelosof

Get full text